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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A310with the reduced Mmp13 and Ptgs2 mRNA detected in the KO animals.
The contribution of Elf3 to load-induced cartilage damage and the
identiﬁcation of targets and mechanism of action in vivo merits further
investigation.
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INHIBITION OF CTX-II RELEASE BY CATHEPSIN K INHIBITION IN VIVO
BUT NOT IN VITRO SUGGESTS THAT ANTI-RESORPTIVE THERAPY
PROTECTS CARTILAGE
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Purpose: Loss of subchondral bone precedes both reduced joint space
in human OA and cartilage loss in animal models. This suggests that
resorption of subchondral bone might cause or aggravate cartilage loss.
Consistent with this, anti-resorptives given in vivo suppress release of
CTX-II, a peptide fragment generated from cleavage of type II collagen,
in several species and prevent disease progression in animal models
and in humans. Thus, loss of subchondral bonemay destabilise cartilage
and induce its degradation by chondrocytes. However, an alternative
explanation for suppression of CTX-II has recently been proposed i.e.
that osteoclasts themselves release CTX-II when they resorb calciﬁed
cartilage, so that there is less release when resorption is inhibited. We
therefore tested whether osteoclasts generate CTX-II from cartilage and
if this was done in a MMP- or cathepsin K-dependent manner. We used
osteoclast-induced CTX-I release from subchondral bone as a com-
parator.We also compared the in vitro datawith the effect of a cathepsin
K inhibitor in vivo on urine CTX-I and CTX-II levels in female beagle dogs
subjected to partial medial meniscectomy, an experimental model of
OA1.
Methods: For the in vitro study, human osteoclasts were incubated on
slices of subchondral bone and overlying calciﬁed and hyaline cartilage
(‘bone-cartilage’) taken from patients with OA. CTX-I and CTX-II levels
were measured after a ﬁrst incubation period for 24 h to establish a
baseline release of the two respective biomarkers. The cultures were
then incubated with the selective cathepsin K inhibitor MV061194 (300
nM, n¼4), or the broad spectrumMMP-inhibitor GM6001 (10 mM, n¼4),
or vehicle (n¼4) for another 24 h. Results were expressed as CTX-I or
CTX-II release compared to baseline. In a previously performed exper-
imental dog OA study, female beagle dogs were subjected to partial
medial meniscectomy and treated with the selective cathepsin K
inhibitor MIV-711 (30 mmol/kg p.o., n¼15) or vehicle (p.o., n¼15) for 28
days starting the day before surgery. Urine was collected for assessment
of CTX-I and CTX-II levels and creatinine. All data are expressed as mean
± SEM.
Results: Osteoclast incubation on the bone-cartilage slices increased
CTX-I levels from <LLQ (0.44 nM) to 155 ± 24 nM. CTX-II levels from the
same slices were increased from 34 ± 6 pg/ml to 533 ± 23 pg/ml. As
expected, the cathepsin K inhibitor MV061194 strongly suppressed
CTX-I release (vehicle controls: 76±13% compared to baseline;
MV061194: 26±4%). However, there was no change in CTX-II release in
presence of the cathepsin K inhibitor (vehicle controls: 92±5% com-
pared to baseline; MV061194: 88±8%). In contrast, the MMP inhibitor
GM6001 reduced CTX-II to 45±5% of baseline release. These data
however do not exclude that osteoclasts could release other cleavage
fragments from type II collagen in a cathepsin K-dependent manner. In
female beagle dogs, after 28-day treatment, the selective cathepsin K
inhibitor MIV-711 reduced urinary CTX-I levels to 14±1% compared to
baseline and CTX-II levels to 20±2%.
Conclusions: Osteoclasts release CTX-I and CTX-II from bone/cartilage
explants in vitro. The CTX-I release in vitro is cathepsin K-dependent
while the CTX-II release is not. By contrast, selective cathepsin K
inhibition reduces urinary levels of CTX-I and CTX-II in a similar fashion
in dog. In dog, these reductions translated into structural beneﬁt on
cartilage1. Thus, this provides evidence that the reduction in CTX-II in
vivo by cathepsin K inhibition is probably not caused by direct sup-
pression of osteoclast-evoked CTX-II release. Rather, direct inhibition of
cathepsin K-mediated bone resorption protects cartilage, and thereby
indirectly reduces the release of CTX-II.
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KNEE KINEMATIC DIFFERENCES IN ANTERIOR CRUCIATE LIGAMENT
DEFICIENT SUBJECTS PRIOR TO RECONSTRUCTION IS ASSOCIATED
WITH KNEE T1r CARTILAGE RELAXATION TIME AT LONGITUDINAL
FOLLOW-UP
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Purpose: This study aimed to identify possible biomechanical markers
in gait alterations in anterior cruciate ligament (ACL)-deﬁcient knees
prior to reconstruction to predict T1r relaxation times.
Methods: Subjects: Motion analysis data were recorded at baseline
(n¼49, female:male¼ 20:29, age: 29.63±8.63 years, BMI: 23.8±2.66 kg/
m2) after injury and before ACL reconstruction. Gait Analysis: At base-
line, three-dimensional motion analysis was captured while subjects
walked at a controlled speed (1.33±0.6667 m/s). Lower-extremity kin-
ematics data were recorded using AMTI force plate (Watertown, MA,
USA, sampling frequency ¼ 1000Hz) and Vicon motion capture system
(Oxford Metrics, UK, sampling frequency ¼ 250 Hz). Joint external
moments and impulses were then computed using Visual3D Software
(C-Motion, Germantown, MD, USA). MR Protocol: Of the 49 subjects
that conducted motion analysis at baseline, 39 patients returned 12
months following surgery to conduct MR imaging of both knees using a
3 Tesla scanner (GE healthcare) and an 8-channel knee coil (Invivo).
Comprehensive cartilage T1r relaxation times were calculated using
previously validated and published methods by our group. Cartilage
was divided into subcompartments to examine regional variations in
cartilage health (Figure 1). Mean T1r relaxation times were calculated
for each global compartment and its corresponding subcompartments.
Statistic Analysis: Pearson product correlation coefﬁcients were calcu-
lated between T1r relaxation times at the 12-month timepoint and gait
characteristics obtained at baseline prior to surgery Variables histor-
ically in literature that could be associated with knee osteoarthritis
were examined, such as peak knee extension adduction moments and
impulses, and hip ﬂexion moments.
Results: In injury knees, baseline lower peak hip ﬂexion moment, lower
peak knee extension moment in the 1st half of stance phase and lower
peak knee adduction moment in the 2nd half of stance phase were
signiﬁcantly correlated with increased cartilage T1p at 12-months.
(Table 1)
